Incanthera PLC (AQSE:INC) has made operational strides in the rollout of its Skin+CELL skincare range, marking its transition from research-led development to commercial activity.
The company launched the brand in August through a dedicated direct-to-consumer website and social media platforms, including Instagram, Facebook and TikTok.
Since launch, the company has recorded steady increases in traffic, engagement and sales conversion.
The B3 Face cream has emerged as the most popular product in the range, which spans face, body, hand, serum and eye care. Instagram was identified as the most effective marketing channel, with consumer feedback described as unanimously positive across demographics.
Scientific data published in June supported the product’s claims, highlighting its reparative effects at the cellular level and UV protection capability. The company said the formulation combines pharmaceutical delivery mechanisms with cosmetic ingredients, offering a new approach to skincare.
Incanthera said it is continuing to refine its promotional strategy using consumer data gathered from its digital channels. Sales have increased post-period, supported by marketing events such as a Black Friday campaign and product-specific discounts.
Alongside its direct-to-consumer efforts, the group remains in discussions over alternative routes to market. “Discussions are progressing with a number of parties on potential collaborations and deals,” said Simon Ward, chief executive.
Looking ahead, the company said its next steps include expanding the brand and developing further product innovations.
The operational progress comes amid continued investment in brand development and marketing infrastructure.
For the six months to 30 September 2025, the company posted a loss of £888,000, compared with a £620,000 loss a year earlier. Cash at the end of the period totalled £215,000.